Veliparib
| Title | Journal |
|---|---|
| Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells. | Nucleic acids research 20161201 |
| CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. | Cell reports 20161122 |
| Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. | The New England journal of medicine 20160707 |
| Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences. | Toxicology letters 20160226 |
| Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy. | Journal of medicinal chemistry 20150910 |
| Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage. | Proceedings of the National Academy of Sciences of the United States of America 20140916 |
| Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. | Cell metabolism 20140603 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. | Molecular pharmacology 20121001 |
| Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. | Molecular pharmacology 20120801 |
| Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. | Molecular therapy : the journal of the American Society of Gene Therapy 20120501 |
| Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus. | Hypertension (Dallas, Tex. : 1979) 20120501 |
| Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation. | Cellular and molecular life sciences : CMLS 20120301 |
| Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. | The Journal of biological chemistry 20120203 |
| Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120115 |
| Novel binding mode of a potent and selective tankyrase inhibitor. | PloS one 20120101 |
| Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. | PloS one 20120101 |
| Bortezomib-induced 'BRCAness' sensitizes multiple myeloma cells to PARP inhibitors. | Blood 20111208 |
| Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. | Cell cycle (Georgetown, Tex.) 20111201 |
| Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. | Cancer biology & therapy 20111115 |
| Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant. | Oncology (Williston Park, N.Y.) 20111115 |
| Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma. | Nuclear medicine communications 20111101 |
| Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. | Cancer science 20111001 |
| Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. | Cancer research 20110901 |
| Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. | Cancer research 20110715 |
| Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. | Molecular cancer therapeutics 20110701 |
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. | The Journal of clinical investigation 20110701 |
| PARP inhibitors: its role in treatment of cancer. | Chinese journal of cancer 20110701 |
| The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20110601 |
| Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. | Nucleic acids research 20110501 |
| N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. | Neuro-oncology 20110501 |
| 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2). | Journal of medicinal chemistry 20110414 |
| MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. | Cancer research 20110401 |
| PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy. | Acta clinica Belgica 20110101 |
| Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. | PloS one 20110101 |
| Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. | PloS one 20110101 |
| Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. | Nature structural & molecular biology 20101001 |
| Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. | Cancer research 20100801 |
| PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. | Cancer research 20100701 |
| A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS. | Journal of pharmaceutical and biomedical analysis 20100501 |
| Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. | Biochemistry 20100216 |
| Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. | Cancer chemotherapy and pharmacology 20100201 |
| Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201 |
| Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. | Cancer journal (Sudbury, Mass.) 20100101 |
| Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. | Breast cancer research : BCR 20100101 |
| ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091201 |
| Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. | Journal of medicinal chemistry 20091112 |
| Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. | Cancer biology & therapy 20091101 |
| Role of Phase 0 trials in drug development. | Future medicinal chemistry 20091101 |
| Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. | Molecular cancer research : MCR 20091001 |
| Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. | Molecular cancer therapeutics 20090801 |
| Phase 0 trials: a platform for drug development? | Lancet (London, England) 20090718 |
| Phase 0 clinical trials: an answer to drug development stagnation? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601 |
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601 |
| Phase 0 trials for anticancer drug development. | Nature reviews. Drug discovery 20090601 |
| Phase zero launch. | Nature biotechnology 20090601 |
| Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. | Molecular cancer therapeutics 20090201 |
| Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. | Journal of medicinal chemistry 20090122 |
| 94th RSNA Annual Meeting. | The Lancet. Oncology 20090101 |
| Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081101 |
| An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. | Analytical biochemistry 20081015 |
| Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. | Molecular cancer research : MCR 20081001 |
| Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901 |
| A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20080801 |
| Phase 0 trials: an industry perspective. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080615 |
| Patient perspectives on phase 0 clinical trials. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080615 |
| Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. | Cancer biology & therapy 20080601 |
| The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. | Anticancer research 20080101 |
| Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070515 |
| ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070501 |